FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023504361> ?p ?o ?g. }

• W2023504361 abstract "Background Different tyrosine-kinase inhibitors (TKIs) have been used in the treatment of metastatic renal cell carcinoma (mRCC), however there is little clinical evidence on which scheme is the best therapeutic alternative. Purpose To analyse the effectiveness of axitinib in the treatment of mRCC according to the therapeutic regimen previously received. Materials and methods Retrospective observational study completed in 2013. All patients with mRCC in treatment with axitinib were included. Variables were: demographics (age, sex), clinical status (stage, reason for stopping treatment) and effectiveness (progression-free survival PFS and overall survival OS). Information sources used were electronic medical records and prescribing history from which sociodemographic, clinical and effectiveness variables were obtained. Results 15 patients were included with an average age of 68 (60% men, 40% women). The reason for stopping treatment was disease progression in 40% of patients and in 6.67% was death. 53.33% are continuing treatment. 40% and 13.33% patients received axitinib in second-line treatment after failure with sunitinib and pazopanib respectively. The remaining 46.67% patients received axitinib for third-line treatment after failure with cytokines and another previous TKI. Median PFS was 9.1 months for the group of patients who received axitinib as second-line treatment after failure with sunitinib. Median OS could not be obtained because none of the patients had died at the end of the study. Median PFS and OS were 3.63 months for patients who received axitinib as second-line treatment after failure with pazopanib. Median PFS and OS were 3.5 and 5.5 months respectively for patients who received axitinib as third-line treatment after failure with cytokines and another previous TKI. Conclusions Axitinib was used starting from second-line treatment. PFS in patients pre-treated with sunitinib was higher than in patients pre-treated with sorafenib or with cytokines and TKIs. This conclusion should be confirmed with further studies that include more patients. No conflict of interest." @default.
• W2023504361 created "2016-06-24" @default.
• W2023504361 creator A5006373296 @default.
• W2023504361 creator A5018137950 @default.
• W2023504361 creator A5032466353 @default.
• W2023504361 creator A5042669000 @default.
• W2023504361 creator A5072043066 @default.
• W2023504361 creator A5073322279 @default.
• W2023504361 date "2014-02-24" @default.
• W2023504361 modified "2023-09-27" @default.
• W2023504361 title "DI-018 Effectiveness of axitinib in the treatment of metastatic renal cell carcinoma in a tertiary hospital" @default.
• W2023504361 doi "https://doi.org/10.1136/ejhpharm-2013-000436.189" @default.
• W2023504361 hasPublicationYear "2014" @default.
• W2023504361 type Work @default.
• W2023504361 sameAs 2023504361 @default.
• W2023504361 citedByCount "0" @default.
• W2023504361 crossrefType "journal-article" @default.
• W2023504361 hasAuthorship W2023504361A5006373296 @default.
• W2023504361 hasAuthorship W2023504361A5018137950 @default.
• W2023504361 hasAuthorship W2023504361A5032466353 @default.
• W2023504361 hasAuthorship W2023504361A5042669000 @default.
• W2023504361 hasAuthorship W2023504361A5072043066 @default.
• W2023504361 hasAuthorship W2023504361A5073322279 @default.
• W2023504361 hasConcept C126322002 @default.
• W2023504361 hasConcept C141071460 @default.
• W2023504361 hasConcept C143998085 @default.
• W2023504361 hasConcept C2776539811 @default.
• W2023504361 hasConcept C2777472916 @default.
• W2023504361 hasConcept C2778439243 @default.
• W2023504361 hasConcept C2779490328 @default.
• W2023504361 hasConcept C2781413609 @default.
• W2023504361 hasConcept C71924100 @default.
• W2023504361 hasConceptScore W2023504361C126322002 @default.
• W2023504361 hasConceptScore W2023504361C141071460 @default.
• W2023504361 hasConceptScore W2023504361C143998085 @default.
• W2023504361 hasConceptScore W2023504361C2776539811 @default.
• W2023504361 hasConceptScore W2023504361C2777472916 @default.
• W2023504361 hasConceptScore W2023504361C2778439243 @default.
• W2023504361 hasConceptScore W2023504361C2779490328 @default.
• W2023504361 hasConceptScore W2023504361C2781413609 @default.
• W2023504361 hasConceptScore W2023504361C71924100 @default.
• W2023504361 hasLocation W20235043611 @default.
• W2023504361 hasOpenAccess W2023504361 @default.
• W2023504361 hasPrimaryLocation W20235043611 @default.
• W2023504361 hasRelatedWork W1486016839 @default.
• W2023504361 hasRelatedWork W1994581907 @default.
• W2023504361 hasRelatedWork W2012236247 @default.
• W2023504361 hasRelatedWork W2074399456 @default.
• W2023504361 hasRelatedWork W2130532651 @default.
• W2023504361 hasRelatedWork W2298717328 @default.
• W2023504361 hasRelatedWork W2480362970 @default.
• W2023504361 hasRelatedWork W2564759327 @default.
• W2023504361 hasRelatedWork W2587585350 @default.
• W2023504361 hasRelatedWork W2589896733 @default.
• W2023504361 hasRelatedWork W2590180656 @default.
• W2023504361 hasRelatedWork W2590340566 @default.
• W2023504361 hasRelatedWork W2762888717 @default.
• W2023504361 hasRelatedWork W2778584590 @default.
• W2023504361 hasRelatedWork W2785103248 @default.
• W2023504361 hasRelatedWork W2905004070 @default.
• W2023504361 hasRelatedWork W2908127196 @default.
• W2023504361 hasRelatedWork W2923738693 @default.
• W2023504361 hasRelatedWork W2996164021 @default.
• W2023504361 hasRelatedWork W3088961826 @default.
• W2023504361 isParatext "false" @default.
• W2023504361 isRetracted "false" @default.
• W2023504361 magId "2023504361" @default.
• W2023504361 workType "article" @default.